Certara, Inc. (NASDAQ:CERT) Shares Acquired by Glenmede Trust Co. NA

Glenmede Trust Co. NA boosted its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 78.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,206,069 shares of the company's stock after purchasing an additional 530,598 shares during the period. Glenmede Trust Co. NA owned about 0.75% of Certara worth $14,123,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. The Manufacturers Life Insurance Company raised its stake in Certara by 4.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company's stock valued at $317,000 after purchasing an additional 975 shares during the period. Louisiana State Employees Retirement System raised its stake in Certara by 2.3% during the 2nd quarter. Louisiana State Employees Retirement System now owns 54,200 shares of the company's stock valued at $751,000 after purchasing an additional 1,200 shares during the period. Nicolet Advisory Services LLC raised its stake in Certara by 6.6% during the 3rd quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company's stock valued at $273,000 after purchasing an additional 1,531 shares during the period. KBC Group NV raised its stake in Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company's stock valued at $57,000 after purchasing an additional 1,584 shares during the period. Finally, Blue Trust Inc. bought a new stake in Certara during the 2nd quarter valued at approximately $26,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Stock Down 0.5 %

Shares of CERT stock traded down $0.06 during mid-day trading on Friday, hitting $11.21. The stock had a trading volume of 497,149 shares, compared to its average volume of 800,621. The firm's 50-day moving average is $10.81 and its two-hundred day moving average is $13.02. Certara, Inc. has a 12-month low of $9.41 and a 12-month high of $19.87. The firm has a market capitalization of $1.80 billion, a P/E ratio of -56.05, a price-to-earnings-growth ratio of 5.70 and a beta of 1.51. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. During the same period in the prior year, the company posted $0.06 EPS. The firm's quarterly revenue was up 10.7% compared to the same quarter last year. On average, analysts predict that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on CERT shares. Barclays decreased their target price on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday, November 7th. UBS Group raised Certara from a "neutral" rating to a "buy" rating and set a $16.00 price objective on the stock in a research note on Friday, September 27th. Finally, Robert W. Baird dropped their target price on Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a report on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $15.92.

Insider Activity at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares of the company's stock, valued at approximately $1,125,658.16. This represents a 33.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This represents a 9.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by corporate insiders.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.